Rhabdomyosarcoma Clinical Trials

26 recruiting

Rhabdomyosarcoma Trials at a Glance

40 actively recruiting trials for rhabdomyosarcoma are listed on ClinicalTrialsFinder across 6 cities in 25 countries. The largest study group is Phase 1 with 23 trials, with the heaviest enrollment activity in Houston, Memphis, and Boston. Lead sponsors running rhabdomyosarcoma studies include St. Jude Children's Research Hospital, Baylor College of Medicine, and Fudan University.

Browse rhabdomyosarcoma trials by phase

Treatments under study

About Rhabdomyosarcoma Clinical Trials

Looking for clinical trials for Rhabdomyosarcoma? There are currently 26 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Rhabdomyosarcoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Rhabdomyosarcoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 40 trials

Recruiting
Phase 1

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

Solid TumorLymphomaGIST+5 more
ITM Solucin GmbH20 enrolled5 locationsNCT06441331
Recruiting

Tumor-Lymph Node Mapping

SarcomaGerm Cell TumorRhabdomyosarcoma+1 more
University of Rochester10 enrolled1 locationNCT07054944
Recruiting
Not Applicable

Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma

Metastatic SarcomaEwing SarcomaRhabdomyosarcoma+1 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins70 enrolled2 locationsNCT06796543
Recruiting
Phase 1Phase 2

VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

Solid TumorRhabdomyosarcoma
University of Texas Southwestern Medical Center23 enrolled7 locationsNCT04796012
Recruiting
Phase 1Phase 2

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

Refractory NeuroblastomaRefractory RhabdomyosarcomaRefractory Solid Tumors+3 more
Theodore Laetsch59 enrolled7 locationsNCT06721689
Recruiting
Phase 1

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

Soft Tissue SarcomaMelanomaCarcinoma+13 more
St. Jude Children's Research Hospital48 enrolled1 locationNCT04897321
Recruiting
Phase 1

Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies

Germ Cell TumorEwing SarcomaNeuroblastoma+3 more
New York Medical College30 enrolled1 locationNCT04308330
Recruiting
Phase 1Phase 2

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Recurrent Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmRecurrent Solid Tumor+19 more
St. Jude Children's Research Hospital90 enrolled10 locationsNCT04901702
Recruiting
Phase 1Phase 2

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

OsteosarcomaEwing SarcomaNeuroblastoma+2 more
Milton S. Hershey Medical Center104 enrolled21 locationsNCT06541262
Recruiting
Phase 1

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

Liver CancerRhabdomyosarcomaWilms Tumor+3 more
Baylor College of Medicine24 enrolled1 locationNCT04715191
Recruiting
Not Applicable

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

MelanomaBreast Cancer, NOSCNS Primary Tumor, NOS+9 more
Eastern Cooperative Oncology Group400 enrolled347 locationsNCT05108298
Recruiting
Phase 1

FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma

Rhabdomyosarcoma
National Cancer Institute (NCI)50 enrolled1 locationNCT06865664
Recruiting

Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone

ChondrosarcomaBone SarcomaChordoma+2 more
Mayo Clinic72 enrolled3 locationsNCT05033288
Recruiting
Phase 1Phase 2

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

OsteosarcomaEwing SarcomaNeuroblastoma+10 more
University of Florida27 enrolled1 locationNCT06625190
Recruiting
Phase 3

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

Embryonal RhabdomyosarcomaFusion-Negative Alveolar RhabdomyosarcomaSpindle Cell/Sclerosing Rhabdomyosarcoma
Children's Oncology Group205 enrolled179 locationsNCT05304585
Recruiting
Phase 1Phase 2

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

SarcomaOsteosarcomaRhabdomyosarcoma+3 more
David S Shulman, MD63 enrolled3 locationsNCT06709495
Recruiting
Phase 1

Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells

Hepatocellular CarcinomaRhabdomyosarcomaWilms Tumor+7 more
Seattle Children's Hospital21 enrolled1 locationNCT07148050
Recruiting
Phase 1

Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas

SarcomaEwing SarcomaChildhood Soft Tissue Sarcoma+2 more
St. Jude Children's Research Hospital42 enrolled1 locationNCT07222735
Recruiting
Phase 1

Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

Ewing SarcomaNeuroblastomaRhabdomyosarcoma+1 more
Children's National Research Institute18 enrolled2 locationsNCT07172958
Recruiting
Phase 2

Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.

Soft Tissue Sarcoma (STS)Soft Tissue Sarcoma AdultSynovial Sarcomas+7 more
Oslo University Hospital40 enrolled2 locationsNCT07173972